Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04836559 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT04836559 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 110 participants.
The verdict
NCT04836559, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are receiving levetiracetam or brivaracetam and up to 3 other anti-epileptic drugs (AEDs) (double-blind treatment period) and to evaluate the long-term efficacy and safety of adjunctive therapy with JNJ-40411813 in participants with epilepsy (open-label extension \[OLE\] period).
Interventions
- DRUG Placebo
- DRUG JNJ-40411813
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2024-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04836559
The ClinicalTrials.gov registry entry for NCT04836559 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04836559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04836559 about?
NCT04836559 is a clinical study titled "A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy". The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are receiving levetiracetam or brivaracetam and up to 3 other anti-epileptic d...
What is the current status of trial NCT04836559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2021-05-18. Estimated completion is 2024-02-08.
What interventions are being tested in trial NCT04836559?
The interventions under investigation include: Placebo (DRUG), JNJ-40411813 (DRUG).
Who is sponsoring clinical trial NCT04836559?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.